JPMorgan Chase & Co’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.69K | Sell |
1,418
-7,061
| -83% | -$8.4K | ﹤0.01% | 5673 |
|
|
2025
Q1 | $17.2K | Sell |
8,479
-17,330
| -67% | -$35.2K | ﹤0.01% | 5329 |
|
|
2024
Q4 | $155K | Sell |
25,809
-8,182
| -24% | -$49.3K | ﹤0.01% | 4627 |
|
|
2024
Q3 | $238K | Buy |
33,991
+28,748
| +548% | +$201K | ﹤0.01% | 4396 |
|
|
2024
Q2 | $30.4K | Buy |
5,243
+284
| +6% | +$1.65K | ﹤0.01% | 5054 |
|
|
2024
Q1 | $35.5K | Sell |
4,959
-28,384
| -85% | -$203K | ﹤0.01% | 5082 |
|
|
2023
Q4 | $164K | Buy |
33,343
+6,771
| +25% | +$33.3K | ﹤0.01% | 4544 |
|
|
2023
Q3 | $254K | Buy |
26,572
+19,645
| +284% | +$188K | ﹤0.01% | 4099 |
|
|
2023
Q2 | $89.8K | Buy |
6,927
+297
| +4% | +$3.85K | ﹤0.01% | 4684 |
|
|
2023
Q1 | $84K | Buy |
+6,630
| New | +$84K | ﹤0.01% | 4716 |
|